Toronto Dominion Bank
HRTX icon

Toronto Dominion Bank’s Heron Therapeutics HRTX Stock Holding History

Toronto Dominion Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9
Closed -$32 – 1275
2024
Q2 		$32 Hold
9
– – ﹤0.01% 1406
2024
Q1 		$25 Hold
9
– – ﹤0.01% 1384
2023
Q4 		$15 Hold
9
– – ﹤0.01% 1551
2023
Q3 		$9 Hold
9
– – ﹤0.01% 1808
2023
Q2 		$0 Hold
9
– – ﹤0.01% 1622
2023
Q1 		$0 Buy
+9
New +$23 ﹤0.01% 1565
2022
Q3 		– Sell
-9
Closed – – 1628
2022
Q2 		$0 Hold
9
– – ﹤0.01% 1580
2022
Q1 		$0 Sell
9
-163,376
-100% -$1.2M ﹤0.01% 1671
2021
Q4 		$1.49M Buy
163,385
+163,376
+1,815,289% +$1.67M ﹤0.01% 918
2021
Q3 		$0 Hold
9
– – ﹤0.01% 1417
2021
Q2 		$0 Sell
9
-30
-77% -$477 ﹤0.01% 1424
2021
Q1 		$1K Sell
39
-60
-61% -$1.07K ﹤0.01% 1412
2020
Q4 		$2K Buy
+99
New +$1.72K ﹤0.01% 1283

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank's HRTX Position: Q3 2024 in Review

Toronto Dominion Bank sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 9 shares — an estimated $32 sold.

Toronto Dominion Bank first reported a position in HRTX in Q4 2020 and held it in 13 quarters. The position peaked at $1.49M in Q4 2021. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Toronto Dominion Bank reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Toronto Dominion Bank sold 9 Heron Therapeutics shares in Q3 2024, an estimated $32.
  • Toronto Dominion Bank first reported a position in Heron Therapeutics in Q4 2020 and held it in 13 quarters.
  • Toronto Dominion Bank's Heron Therapeutics position peaked at $1.49M in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Toronto Dominion Bank's 13F filing for Q3 2024, filed 14 Nov 2024.